Tornier, LifeCell in pig-tissue matrix pact
This article was originally published in Clinica
Executive Summary
Extremity orthopaedics specialist Tornier has teamed up with regenerative human tissue company LifeCell, to distribute the latter's new-generation reconstructive tissue matrix. The exclusive deal, of which no financial details were disclosed, will see the two firms work together to develop the product for orthopaedic soft tissue repair applications such as tendon repair. Tornier will then distribute the product to orthopaedic and podiatric surgeons under the brand name Conexa. The product is already approved by the FDA for these applications. The new tissue matrix uses porcine-derived tissue technology which, according to Edina, Minnesota-based Tornier, is equally as effective at promoting tissue regeneration as the company's flagship human tissue matrix, AlloDerm.
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.